secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001628280-25-010777
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE reports FY2024 net loss $39.8M; cash $61.5M; repibresib Phase 2b data due mid-2025
--------------------------------------------------------------------------------

- Cash & equivalents total $61.5M as of Dec 31, 2024; expected runway into 2H 2026.
- Net loss for FY 2024 was $39.8M ($0.93 per share) vs $28.5M ($2.78 per share) in 2023.
- R&D expenses doubled to $30.9M driven by Phase 2b repibresib and Phase 1a VYN202 trials.
- Repibresib gel Phase 2b vitiligo top-line data expected mid-2025; fully enrolled ~180 subjects.
- VYN202 Phase 1b psoriasis trial initiated; top-line results expected by year-end 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000162828025010777/0001628280-25-010777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000162828025010777/mnlo-20250306.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-010777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer